{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:25:21Z","timestamp":1795040721420,"version":"4.10.2"},"reference-count":35,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP). A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia. Eleven of those patients also experienced clinically compromising anemia, transfusion with packed red blood cells, renal insufficiency, dialysis, or death. That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (DIC). Through November 30, 2004, the FDA received 6 reports of DIC associated with \u201cacute hemolysis\u201d (or similar terms), 5 of which involved fatalities. The attending or consulting physicians assessed that acute hemolysis or DIC caused or contributed to each death. This review presents the first case series of DIC associated with acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP. The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of anti-D IGIV treatment. Increased awareness of DIC as a diagnostic possibility may enable prompt recognition and medical intervention in affected patients.<\/jats:p>","DOI":"10.1182\/blood-2004-11-4303","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T20:29:45Z","timestamp":1115411385000},"page":"1532-1537","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":125,"title":["Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura"],"prefix":"10.1182","volume":"106","author":[{"given":"Ann Reed","family":"Gaines","sequence":"first","affiliation":[{"name":"From the Division of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021220053698800_REF1","unstructured":"Rho(D) immune globulin intravenous (Human): WinRho\u00ae SDF. Cangene Corporation, Winnipeg, MB, Canada R3T 5Y3 [professional package insert], October 2004."},{"key":"2020021220053698800_REF2","unstructured":"Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M. Safety profile of WinRho anti-D. Semin Hematol. 1998;35(suppl 1): 9-13."},{"key":"2020021220053698800_REF3","doi-asserted-by":"crossref","unstructured":"Gaines AR. Acute onset hemoglobinemia and\/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous (human) administration in immune thrombocytopenic purpura patients. Blood. 2000;95: 2523-2529.","DOI":"10.1182\/blood.V95.8.2523"},{"key":"2020021220053698800_REF4","doi-asserted-by":"crossref","unstructured":"Roberti I, Bagtas J, Reisman L, Murphy S. Severe acute renal failure due to hemoglobinuria after use of WinRho for the treatment of idiopathic thrombocytopenic purpura [letter]. Clin Pediatr. 2001;40: 61-62.","DOI":"10.1177\/000992280104000114"},{"key":"2020021220053698800_REF5","doi-asserted-by":"crossref","unstructured":"Olofinboba KA, Greenberg BR. Successful treatment of infectious mononucleosis-associated immune thrombocytopenia with WinRho anti-D immunoglobulin complicated by severe hemolysis [letter]. Am J Hematol. 2000;65: 178.","DOI":"10.1002\/1096-8652(200010)65:2<178::AID-AJH18>3.0.CO;2-G"},{"key":"2020021220053698800_REF6","doi-asserted-by":"crossref","unstructured":"Levendoglu-Tugal O, Somasundaram J. Intravenous anti-D immune globulin-induced intravascular hemolysis in Epstein-Barr virus-related thrombocytopenia. J Pediatr Hematol Oncol. 2001;23: 460-463.","DOI":"10.1097\/00043426-200110000-00014"},{"key":"2020021220053698800_REF7","doi-asserted-by":"crossref","unstructured":"Kees-Folts D, Abt AB, Domen RE, Freiberg AS. Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. Pediatr Nephrol. 2002;17: 91-96.","DOI":"10.1007\/s00467-001-0763-4"},{"key":"2020021220053698800_REF8","doi-asserted-by":"crossref","unstructured":"Chun NS, Savani B, Seder RH, Taplin ME. Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. Am J Hematol. 2003;74: 276-279.","DOI":"10.1002\/ajh.10432"},{"key":"2020021220053698800_REF9","unstructured":"Parker C. Intravenous Rho[D] immune globulin [human] (WinRho SDF): suspected hemolytic\/renal adverse reactions. Can Adverse Drug React Newsl. 2000;10(4): 6."},{"key":"2020021220053698800_REF10","doi-asserted-by":"crossref","unstructured":"Rewald MDE, Francischetti MM. After eight-year-tolerance minimal i.v. anti-D infusions unleash hemolysis in a patient with immune thrombocytopenic purpura (ITP). Transfus Apheresis Sci. 2004;30: 105-110.","DOI":"10.1016\/j.transci.2003.09.001"},{"key":"2020021220053698800_REF11","unstructured":"Brecher ME, ed. Technical Manual. 14th ed. Bethesda, MD: American Association of Blood Banks; 2002."},{"key":"2020021220053698800_REF12","unstructured":"Anderson KC, Ness PM, eds. Scientific Basis of Transfusion Medicine: Implications for Clinical Practice, 2nd ed. Philadelphia, PA: WB Saunders; 2000."},{"key":"2020021220053698800_REF13","unstructured":"Greer J, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds. Wintrobe's Clinical Hematology. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004."},{"key":"2020021220053698800_REF14","unstructured":"Simon TL, Dzik WH, Stowell CP, Snyder EL, Strauss RG, eds. Rossi's Principles of Transfusion Medicine. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002."},{"key":"2020021220053698800_REF15","unstructured":"Beutler E, Coller BS, Lichtman MA, Kipps TJ, Seligsohn U, eds. Williams Hematology. 6th ed. New York, NY: McGraw-Hill; 2001."},{"key":"2020021220053698800_REF16","unstructured":"Strom BL, ed. Pharmacoepidemiology. 2nd ed. New York, NY: John Wiley & Sons; 1994."},{"key":"2020021220053698800_REF17","unstructured":"IMS Health, National Sales Perspectives, Non-Retail, Year 1994 through 1998, data extracted April 1999."},{"key":"2020021220053698800_REF18","unstructured":"IMS Health, National Sales Perspectives, Non-Retail, Year 1999 through 2003, extracted August 2004."},{"key":"2020021220053698800_REF19","unstructured":"IMS Health, National Sales Perspectives, Non-Retail, Year to Date January-November 2004, data extracted February 2005."},{"key":"2020021220053698800_REF20","doi-asserted-by":"crossref","unstructured":"Longhurst HJ, O'Grady C, Evans G, et al. Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency. J Clin Pathol. 2002;55: 64-66.","DOI":"10.1136\/jcp.55.1.64"},{"key":"2020021220053698800_REF21","doi-asserted-by":"crossref","unstructured":"Sandler SG. Intravenous Rh immune globulin for treating immune thrombocytopenic purpura. Curr Opin Hematol. 2001;8: 417-420.","DOI":"10.1097\/00062752-200111000-00017"},{"key":"2020021220053698800_REF22","doi-asserted-by":"crossref","unstructured":"Kessler D. Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993; 269: 2765-2768.","DOI":"10.1001\/jama.1993.03500210065033"},{"key":"2020021220053698800_REF23","doi-asserted-by":"crossref","unstructured":"Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281: 824-829.","DOI":"10.1001\/jama.281.9.824"},{"key":"2020021220053698800_REF24","doi-asserted-by":"crossref","unstructured":"Bortnichak EA, Dai WS. Epidemiologists and adverse event data\u2014a challenge to the field. Pharmacoepidemiol Drug Saf. 1999;8: 457-461.","DOI":"10.1002\/(SICI)1099-1557(199910\/11)8:6<457::AID-PDS452>3.0.CO;2-S"},{"key":"2020021220053698800_REF25","doi-asserted-by":"crossref","unstructured":"Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(suppl C): C40-C44.","DOI":"10.1016\/S0149-2918(98)80007-6"},{"key":"2020021220053698800_REF26","doi-asserted-by":"crossref","unstructured":"Trontell AE. How the US Food and Drug Administration defines and detects adverse drug events. Curr Ther Res. 2001;62: 641-649.","DOI":"10.1016\/S0011-393X(01)80070-9"},{"key":"2020021220053698800_REF27","doi-asserted-by":"crossref","unstructured":"Hartnell NR, Wilson JP, Patel NC, Crismon ML. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother. 2003;37: 1387-1391.","DOI":"10.1345\/aph.1C522"},{"key":"2020021220053698800_REF28","unstructured":"Rho(D) immune globulin iv for prevention of Rh isoimmunization and for treatment of ITP. Med Lett Drugs Ther. 1996;38: 6-8."},{"key":"2020021220053698800_REF29","doi-asserted-by":"crossref","unstructured":"Hartwell EA. Use of Rh immune globulin: ASCP practice parameter. Am J Clin Pathol. 1998;110: 281-292.","DOI":"10.1093\/ajcp\/110.3.281"},{"key":"2020021220053698800_REF30","doi-asserted-by":"crossref","unstructured":"Garratty G. Problems associated with passively transfused blood group alloantibodies. Am J Clin Pathol. 1998;109: 769-777.","DOI":"10.1093\/ajcp\/109.6.769"},{"key":"2020021220053698800_REF31","unstructured":"Hemolysis associated with 25% human albumin diluted with sterile water\u2014United States, 1994-1998. MMWR Morb Mortal Wkly Rep. 1999;48: 157-159."},{"key":"2020021220053698800_REF32","unstructured":"MedWatch: important prescribing information. US Food and Drug Administration. Available at: www.fda.gov\/medwatch\/safety\/2000\/winrho.html. January 2000. Accessed April 21, 2005."},{"key":"2020021220053698800_REF33","doi-asserted-by":"crossref","unstructured":"Rushin J, Rumsey DH, Ewing CA, Sandler SG. Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin. Transfusion. 2000;40: 551-554.","DOI":"10.1046\/j.1537-2995.2000.40050551.x"},{"key":"2020021220053698800_REF34","doi-asserted-by":"crossref","unstructured":"Imbach P, Kuhne T. Sequelae of treatment of ITP with anti-D (Rho) immunoglobulin [commentary]. Lancet. 2000;356: 447-448.","DOI":"10.1016\/S0140-6736(00)02549-6"},{"key":"2020021220053698800_REF35","unstructured":"Baxter Healthcare Corporation. WinRho SDF patients & caregivers. Available at: http:\/\/www.winrho.com\/patients\/index.html. Accessed April 21, 2005."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/5\/1532\/1712758\/zh801705001532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/5\/1532\/1712758\/zh801705001532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:30:39Z","timestamp":1581539439000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/5\/1532\/21453\/Disseminated-intravascular-coagulation-associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-11-4303","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,1]]}}}